Phase 3

Active (not recruiting)

NCT05084053

TAK-771 (Subcutaneous Ig + rHuPH20)

View on ClinicalTrials.gov ↗

Timeline

Study Dates

Start Date

January 2022

Est. Completion

—

Enrollment Target

—

Status

Active (not recruiting)

Study Design

Primary Endpoint

Efficacy, safety, tolerability of TAK-771 in CIDP and MMN (Japanese subjects)

Registry

ClinicalTrials.gov Record

Registry ID

NCT05084053

Direct Link

clinicaltrials.gov/NCT05084053 ↗

Related Treatment

Treatment Being Studied

TAK-771 (Subcutaneous Ig + rHuPH20) →